The Board of Directors of Procter & Gamble Hygiene and Health Care Limited (NSE:PGHH) approved unaudited financial results for the quarter ended 30 June 2026 at a meeting held on 29 July 2026. The company reported net profit of Rs 12,627 lakhs for Q1 FY27, representing a year-on-year decline of 34.2% compared to Rs 19,206 lakhs in the corresponding quarter of FY26. Revenue from operations stood at Rs 89,146 lakhs, down 4.9% YoY.
Key Highlights
- Q1 FY27 net profit fell to Rs 12,627 lakhs from Rs 19,206 lakhs in Q1 FY26, a decline of 34.2% year-on-year.
- Revenue from operations decreased 4.9% to Rs 89,146 lakhs in Q1 FY27 versus Rs 93,703 lakhs in Q1 FY26.
- Profit before tax declined to Rs 16,963 lakhs in Q1 FY27 from Rs 26,470 lakhs in Q1 FY26, a fall of 35.9%.
- Earnings per share (basic and diluted) on a face value of Rs 10 per share was Rs 38.90 in Q1 FY27, down from Rs 59.17 in Q1 FY26.
- The unaudited results were subjected to a limited review by statutory auditors and prepared in accordance with Ind AS 34.
- Finance costs increased to Rs 311 lakhs in Q1 FY27 from Rs 27 lakhs in Q1 FY26, reflecting a near 11-fold rise.
- Total comprehensive income for Q1 FY27 was Rs 12,734 lakhs compared to Rs 19,029 lakhs in Q1 FY26.
About the Company
Procter & Gamble Hygiene and Health Care Limited (NSE:PGHH) is a consumer health and hygiene products manufacturer and marketer listed on the National Stock Exchange of India. The company manufactures, trades, and markets a range of health care and hygiene products including ointments, creams, cough drops, tablets, feminine hygiene products, and skin care hygiene items. Headquartered in Mumbai at P&G Plaza on Cardinal Gracias Road, Chakala, Andheri (East), the company holds paid-up equity capital of Rs 3,246 lakhs with a face value of Rs 10 per equity share. The company operates as a single reportable business segment aggregating health care and hygiene product manufacturing and distribution, and holds no subsidiaries, associates, or joint ventures as of 30 June 2026.
Announcement in Detail
The Board of Directors of Procter & Gamble Hygiene and Health Care Limited convened on 29 July 2026 at 11:56 A.M. and concluded at 12:45 P.M. to review and approve the unaudited financial results for the quarter ended 30 June 2026. The statutory auditors, Kalyaniwalla & Mistry LLP, conducted a limited review under Standard on Review Engagements 2410 and issued a review report confirming that nothing came to their attention suggesting the financial statement did not contain material misstatement or failed to disclose required information under Regulation 33 of the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015.
For the first quarter of FY27, the company reported sale of products at Rs 88,992 lakhs and other operating revenues of Rs 154 lakhs, aggregating to revenue from operations of Rs 89,146 lakhs. Total income, including other income of Rs 943 lakhs, amounted to Rs 90,089 lakhs. Total expenses were reported at Rs 73,126 lakhs, resulting in profit before tax of Rs 16,963 lakhs. After income tax expense of Rs 4,336 lakhs comprising current tax of Rs 4,389 lakhs and deferred tax benefit of Rs 53 lakhs, net profit for the quarter was Rs 12,627 lakhs. Other comprehensive income amounted to Rs 107 lakhs, inclusive of a remeasurement gain of Rs 143 lakhs on defined benefit plans and an associated tax effect of Rs 36 lakhs.
Notably, finance costs surged to Rs 311 lakhs in Q1 FY27 from Rs 27 lakhs in Q1 FY26, an 11-fold increase year-on-year. Raw material and packing material consumption rose to Rs 20,024 lakhs from Rs 16,440 lakhs, while purchases of stock-in-trade increased to Rs 21,323 lakhs from Rs 20,248 lakhs. Advertising and sales promotion expenses declined significantly to Rs 8,332 lakhs in Q1 FY27 from Rs 6,873 lakhs in Q1 FY26, though employee benefits expense decreased to Rs 5,436 lakhs from Rs 4,835 lakhs.
Impact on Investors
Investors will note that the 34.2% year-on-year contraction in net profit represents a material earnings decline in the first quarter. The profit before tax decline of 35.9% points to operational challenges beyond tax effects. Earnings per share contracted to Rs 38.90 from Rs 59.17, a 34.2% fall that directly impacts per-share valuation metrics. The filing shows that while revenue from operations declined modestly by 4.9%, the profit decline was more severe, indicating margin compression through the reporting period. Revenue contraction combined with significant cost pressures suggests operating leverage worked adversely in this quarter.
The dramatic 11-fold surge in finance costs warrants specific attention from investors and analysts. Finance costs rising from Rs 27 lakhs to Rs 311 lakhs indicates materially higher borrowing or financial obligations in the current quarter compared to the year-ago period. This cost escalation directly impacted reported profitability independent of operational performance. Shareholders observing the data will note that despite gross margin pressures evidenced by higher raw material and stock-in-trade costs, discretionary advertising spend was reduced by 17.1% to Rs 8,332 lakhs, suggesting near-term cost management responses. The company's paid-up equity capital remains unchanged at Rs 3,246 lakhs, and no subsidiaries, associates, or joint ventures are present, indicating a standalone operational structure.
Sector / Market Context
The consumer health and hygiene products sector in India includes manufacturers of over-the-counter health items, feminine hygiene products, and personal care products sold through retail and distribution channels. The sector serves a market spanning urban and semi-urban consumers across age groups and income levels. Input cost pressures, including raw material inflation and packaging material costs, have remained a sector-wide challenge. Distribution and promotional intensity compete with margin preservation, and companies in this space often adjust advertising budgets in response to demand conditions and competitive positioning. The unaudited quarter under review reflects these sector dynamics as players manage cost inflation while defending revenue volumes and market share in a competitive consumer products market.